Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tumoricidal biological response modifiers (BRM)].

Y Niitsu1, Y Kohgo, N Watanabe

  • 1Dept. of Internal Medicine (Section 4), Sapporo Medical College.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Seasonal fluctuations of substance P and vasoactive intestinal peptide concentrations in nasal secretions of patients with nasal allergy to Japanese cedar pollen].

Arerugi = [Allergy]·1992
Same author

The 11q- syndrome with mosaic partial deletion of 11q.

Acta paediatrica Japonica : Overseas edition·1992
Same author

Effect of slow release nifedipine tablets in patients with essential hypertension.

Arzneimittel-Forschung·1992
Same author

Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity.

Cancer research·1992
Same author

Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.

The Journal of antimicrobial chemotherapy·1992
Same author

Tumor cytostasis mediated by LPS- or PSK-activated human plastic-adherent peripheral blood mononuclear cells.

Cellular immunology·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Combining biological response modifiers (BRMs) like TNF and IFN with carcinostatic agents offers a rational approach to cancer treatment. This strategy enhances anti-cancer effects by targeting tumor cells through distinct mechanisms and overcoming resistance.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Context:

  • Biological response modifiers (BRMs) such as Tumor Necrosis Factor (TNF), Interferon (IFN), Lymphotoxin (LT), and Interleukin-1 (IL-1) possess inherent cytocidal activity against cancer cells.
  • Unlike conventional carcinostatic agents that directly interact with cellular targets like DNA/RNA, BRMs elicit their cytotoxic effects through receptor-mediated enzyme responses.
  • Cancer cells can develop resistance to BRMs due to counteracting proteins, necessitating alternative therapeutic strategies.

Purpose:

  • To explore the rationale and efficacy of combining BRMs with carcinostatic agents for cancer therapy.
  • To investigate combination therapies that leverage distinct mechanisms of action to enhance anti-cancer outcomes.
  • To evaluate the potential of modulating the immune system through combined BRM and carcinostatic agent administration, including enhancing T-cell-based immunotherapies like TIL and LAK activated by IL-2.

Related Experiment Videos

Summary:

  • The cytocidal action of BRMs is mediated by enzyme responses triggered upon receptor binding, distinct from the direct molecular interactions of carcinostatic drugs.
  • Combination therapy is rationalized by the differing mechanisms of action of BRMs and carcinostatic agents, and by targeting resistance mechanisms in refractory cancer cells.
  • The paper reviews findings from animal models and clinical cases examining the combined use of BRMs and carcinostatic agents, including cyclophosphamide (CY), to enhance immune responses and therapeutic effects.

Impact:

  • Demonstrates the synergistic potential of combining immunomodulatory and cytotoxic agents in cancer treatment.
  • Provides a scientific basis for developing novel combination therapies to overcome drug resistance and improve patient outcomes.
  • Highlights the importance of understanding cellular response mechanisms for optimizing cancer treatment strategies.